Drug Deal Disclosure Act

Key Points

• This bill would require the Department of Health and Human Services to publicly release all records related to drug pricing deals made between the federal government and pharmaceutical manufacturers since January 20, 2025. This includes contracts, emails, meeting notes, and metadata tied to agreements with 16 named companies.
• The deals covered include agreements where drug companies offered lower prices based on what other countries pay, offered direct-to-consumer sales through platforms like TrumpRx, received tariff exemptions, or got special treatment in Medicare demonstration projects like the GLOBE and GUARD models.
• The government could not withhold documents just because releasing them would be embarrassing or politically sensitive. Any redactions for legitimate business reasons would need a written justification published in the Federal Register and submitted to Congress.
• The Congressional Budget Office and Government Accountability Office would have 90 days to jointly analyze the deals' real-world effects, including cost savings broken down by insurance status, impacts on Medicare, Medicaid, and ACA marketplace plans, and whether the deals hurt competition from generic drugs.